Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Multi-Arm (Basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination With Pembrolizumab, as First-Line Treatment for Patients With Metastatic NSCLC, SCCHN, or Metastatic mUBC

Next Previous
Trial Profile

A Phase II Multi-Arm (Basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination With Pembrolizumab, as First-Line Treatment for Patients With Metastatic NSCLC, SCCHN, or Metastatic mUBC

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adjuvanted imsapepimut and etimupepimut (Primary) ; Pembrolizumab (Primary)
  • Indications Adenocarcinoma; Bladder cancer; Carcinoma; Head and neck cancer; Non-small cell lung cancer; Oropharyngeal cancer; Pelvic cancer; Renal cancer; Squamous cell cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
  • Focus Therapeutic Use
  • Acronyms Basket trial
  • Sponsors IO Biotech

Most Recent Events

  • 14 Aug 2025 According to an IO Biotech media release, company continues to expect initial data from this trial to be available in the second half of 2025 and presented at a medical meeting in 2026.
  • 04 Mar 2025 According to IO Biotech media release, company expects longer-term from this trial in the second half of 2025.
  • 04 Mar 2025 Primary endpoint(ORR or PFS) has been met, according to a IO Biotech media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top